Differences between revisions 13 and 14
Revision 13 as of 2005-11-28 15:37:09
Size: 2599
Editor: mskresolve-b
Comment:
Revision 14 as of 2005-11-28 15:56:59
Size: 3319
Editor: mskresolve-b
Comment:
Deletions are marked like this. Additions are marked like this.
Line 30: Line 30:
==== Cytoscape #3: ==== ==== Cytoscaper #3: ====
Line 38: Line 38:
==== Cytoscaper #4: ====
Line 39: Line 40:
  * I thinks we focused on the right set of features. The most important thing is a stable API and being able to support plugin writers better.
  * Nonetheless, we dropped a few features that I wanted. This is probably because I didn't do a good enough job of communicating to others what I was working on.
  * Some groups doing core development are set on maintaining current functionality without soliciting feedback from other groups / users.
  * Quality of 2.2 is much higher than that of 2.1.
  * Need to better differentiate between core and not so core. If we had less stuff in the core, we could do updates of plugins more frequently, and updates to the core less frequently.

About this Document

This is an official Request for Comment (RFC) for "improving the quality of the Cytoscape 2.3 release."

RFC 2 is divided in two parts:

  • Part I consists of Ethan's interviews with six Cytoscapers (Trey, Gary, Ben, Allan, Aditya, and Rowan). I had hoped to interview more people before the Cytoscape retreat, but unfortunately didn't have time to get to everybody. In Part I, I have done my best to paraphrase people's comments, and I have not indicidated who said what.
  • Part II consists of ideas which were culled from Ethan's interviews, and are now presented as concrete proposals to the larger group.

Status

This document is under construction.

Part I: The Interviews

Q1: What do you feel about the quality of the 2.2 release?

Cytosaper #1:

  • We pushed the release date out too much. We should have coordinated our efforts much earlier; we probably could have done something by August. We could have done a much better job if we had coordinated earlier on. I think this compromised the quality of the chosen feature set.
  • Next time, we need to decide the feature set straight away. Then, do design and implementation in the next 2-3 months, so that we can do a real six month release cycle.
  • Feature set was based on developer interests, not really based on user's feedback. We need a better mechanism to get more feedback from real users.

Cytoscaper #2:

  • I think we chose the right set of features. For example, we chose a set of features that go well together, e.g. the new attribute browse goes well with the CytoPanel API. Plus, the editor fits in. Metanodes could have been in there too, and that would have been nice.

  • Timeliness could have been better. Quality could have been better.
  • That said, there are always trade-offs. In the tradeoff between: GraphObjAttributes v. CytoscapeData v. CyAttributes, I think we made the right decision. If we have had put Cytoscape 2.2 out the door a month ago without CyAttributes, it would have been a lot buggier.

Cytoscaper #3:

  • I think we picked the right feature set.
  • Reasonable quality, but could be very much improved.
  • Smoothness of the user experience and user interace (GUI) is still a real issue.
  • Reviewed code is pretty high quality.
  • Release was slow, and could have been faster. We didn't work through all the dependencies between modules early enough.

Cytoscaper #4:

  • I thinks we focused on the right set of features. The most important thing is a stable API and being able to support plugin writers better.
  • Nonetheless, we dropped a few features that I wanted. This is probably because I didn't do a good enough job of communicating to others what I was working on.
  • Some groups doing core development are set on maintaining current functionality without soliciting feedback from other groups / users.
  • Quality of 2.2 is much higher than that of 2.1.
  • Need to better differentiate between core and not so core. If we had less stuff in the core, we could do updates of plugins more frequently, and updates to the core less frequently.

Part II: The Recommendations

Under Construction

RFC_2 (last edited 2009-02-12 01:04:11 by localhost)

Funding for Cytoscape is provided by a federal grant from the U.S. National Institute of General Medical Sciences (NIGMS) of the Na tional Institutes of Health (NIH) under award number GM070743-01. Corporate funding is provided through a contract from Unilever PLC.

MoinMoin Appliance - Powered by TurnKey Linux